GT-Repeat Polymorphism in the HO-1 Gene Promoter Is Associated with Risk of Liver Cancer: A Follow-Up Study from Arseniasis-Endemic Areas in Taiwan

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Apr 30

PMID 33916685

Citations 2

Authors

Meei-Maan Wu

Fang-I Hsieh

Ling-I Hsu

Te-Chang Lee

Hung-Yi Chiou

Chien-Jen Chen

Affiliations

Soon will be listed here.

Abstract

The induction of heme oxygenase-1 (HO-1) has been shown to have therapeutic potential in experimental models of hepatitis and liver fibrosis, which are closely related to liver cancer. In humans, HO-1 induction is transcriptionally modulated by the length of a GT-repeat [(GT)n] in the promoter region. We aimed to investigate the effect of HO-1 (GT)n variants on liver cancer in a human population. We determined the HO-1 genotype in 1153 study subjects and examined their association with liver cancer risk during a 15.9-year follow-up. Allelic polymorphisms were classified as short [S, <27 (GT)n] or long [L, ≥27 (GT)n]. Newly developed cancer cases were identified through linkage to the National Cancer Registry of Taiwan. Multivariate Cox regression analysis was used to evaluate the effect of the HO-1 (GT)n variants. Alpha-fetoprotein (AFP) and cirrhosis history were also examined. The S/S genotype was found to be significantly associated with liver cancer risk, compared to the L/S and L/L genotypes. The S/S genotype group also had a higher percentage of subjects with abnormal AFP levels than other groups. There were significant percentages of cirrhosis among groups who carried S-alleles. Our findings indicate that short (GT)n variants in the HO-1 gene may confer susceptibility to rather than protection from liver cirrhosis/cancer.

Citing Articles

The NRF-2/HO-1 Signaling Pathway: A Promising Therapeutic Target for Metabolic Dysfunction-Associated Steatotic Liver Disease.

Li N, Hao L, Li S, Deng J, Yu F, Zhang J J Inflamm Res. 2024; 17:8061-8083.

PMID: 39512865 PMC: 11542495. DOI: 10.2147/JIR.S490418.

SNP (A > G - rs13057211) but not GT(n) polymorphism in HMOX-1 promotor gene is associated with COVID-19 mortality.

Fares K, El-Deeb M, Elsammak O, Ouf A, Saeed H, Baess A BMC Pulm Med. 2023; 23(1):514.

PMID: 38129860 PMC: 10734135. DOI: 10.1186/s12890-023-02785-x.

References

TSENG W . Effects and dose--response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect. 1977; 19:109-19. PMC: 1637425. DOI: 10.1289/ehp.7719109. View

Hsu L, Wang Y, Hsieh F, Yang T, Wen-Juei Jeng R, Liu C . Effects of Arsenic in Drinking Water on Risk of Hepatitis or Cirrhosis in Persons With and Without Chronic Viral Hepatitis. Clin Gastroenterol Hepatol. 2016; 14(9):1347-1355.e4. DOI: 10.1016/j.cgh.2016.03.043. View

Chen C, Kuo T, Wu M . Arsenic and cancers. Lancet. 1988; 1(8582):414-5. DOI: 10.1016/s0140-6736(88)91207-x. View

Was H, Dulak J, Jozkowicz A . Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets. 2010; 11(12):1551-70. DOI: 10.2174/1389450111009011551. View

Zhu Z, Wilson A, Luxon B, Brown K, Mathahs M, Bandyopadhyay S . Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?. Hepatology. 2010; 52(6):1897-905. PMC: 3058505. DOI: 10.1002/hep.23921. View

Li L, Grenard P, Tran Van Nhieu J, Julien B, Mallat A, Habib A . Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology. 2003; 125(2):460-9. DOI: 10.1016/s0016-5085(03)00906-5. View

Wu M, Kuo T, Hwang Y, Chen C . Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol. 1989; 130(6):1123-32. DOI: 10.1093/oxfordjournals.aje.a115439. View

Chen Y, Lin S, Lin M, Tsai H, Chen J, Charng M . Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet. 2002; 111(1):1-8. DOI: 10.1007/s00439-002-0769-4. View

Zou C, Zhang H, Li Q, Xiao H, Yu L, Ke S . Heme oxygenase-1: a molecular brake on hepatocellular carcinoma cell migration. Carcinogenesis. 2011; 32(12):1840-8. DOI: 10.1093/carcin/bgr225. View

10.

Wu M, Chiou H, Chen C, Wang Y, Hsieh Y, Lien L . GT-repeat polymorphism in the heme oxygenase-1 gene promoter is associated with cardiovascular mortality risk in an arsenic-exposed population in northeastern Taiwan. Toxicol Appl Pharmacol. 2010; 248(3):226-33. DOI: 10.1016/j.taap.2010.08.005. View

11.

Maines M . Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 1988; 2(10):2557-68. View

12.

. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157-63. DOI: 10.1016/S0140-6736(03)15268-3. View

13.

Bukowska-Strakova K, Wlodek J, Pitera E, Kozakowska M, Konturek-Ciesla A, Ciesla M . Role of Promoter Genetic Variants in Chemoresistance and Chemotherapy Induced Neutropenia in Children with Acute Lymphoblastic Leukemia. Int J Mol Sci. 2021; 22(3). PMC: 7863945. DOI: 10.3390/ijms22030988. View

14.

Kazemi M, Khosravian F, Sameti A, Moafi A, Merasi M, Salehi M . Association between (GT)n Repeats in Heme Oxygenase-1 Gene Promoter and 3-Year Survival of Patients with Acute Leukemia: a Controlled, Cross-Sectional Study. Int J Hematol Oncol Stem Cell Res. 2018; 12(1):49-56. PMC: 6018253. View

15.

Wu M, Chiou H, Lee T, Chen C, Hsu L, Wang Y . GT-repeat polymorphism in the heme oxygenase-1 gene promoter and the risk of carotid atherosclerosis related to arsenic exposure. J Biomed Sci. 2010; 17:70. PMC: 2939596. DOI: 10.1186/1423-0127-17-70. View

16.

Lehmann E, El-Tantawy W, Ocker M, Bartenschlager R, Lohmann V, Hashemolhosseini S . The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology. 2010; 51(2):398-404. DOI: 10.1002/hep.23339. View

17.

. Some drinking-water disinfectants and contaminants, including arsenic. IARC Monogr Eval Carcinog Risks Hum. 2005; 84:1-477. PMC: 7682301. View

18.

Kah J, Volz T, Lutgehetmann M, Groth A, Lohse A, Tiegs G . Haem oxygenase-1 polymorphisms can affect HCV replication and treatment responses with different efficacy in humanized mice. Liver Int. 2016; 37(8):1128-1137. DOI: 10.1111/liv.13347. View

19.

Yu J, Chu E, Wang R, Wang S, Wu C, Wong V . Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice. Gastroenterology. 2009; 138(2):694-704, 704.e1. DOI: 10.1053/j.gastro.2009.09.058. View

20.

Lavrovsky Y, Schwartzman M, Levere R, Kappas A, Abraham N . Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci U S A. 1994; 91(13):5987-91. PMC: 44122. DOI: 10.1073/pnas.91.13.5987. View